[1] |
van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update[J]. J Crohns Colitis, 2020, jjaa161.
|
[2] |
Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2019, 25(12): 1896-1905.
doi: 10.1093/ibd/izz059
pmid: 30934053
|
[3] |
中华医学会儿科学分会消化学组, 中华医学会儿科学分会临床营养学组. 儿童炎症性肠病诊断和治疗专家共识[J]. 中华儿科杂志, 2019, 57(7): 501-507.
|
|
Subspecialty Group of Gastroenterology, the Society of Pediatrics, Chinese Medical Association; Subspecialty Group of Clinical Nutrition, the Society of Pediatrics, Chinese Medical Association. Chinese Medical Association. Expert consensus on the diagnosis and management of pediatric inflammatory bowel disease[J]. Zhonghua Erke Zazhi, 2019, 57(7): 501-507.
|
[4] |
Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification[J]. Inflamm Bowel Dis, 2011, 17(6): 1314-1321.
doi: 10.1002/ibd.21493
pmid: 21560194
|
[5] |
Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index[J]. J Pediatr Gastroenterol Nutr, 1991, 12(4): 439-447.
|
[6] |
Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity score in crohn's disease[J]. Saudi J Gastroenterol, 2016, 22(3): 183-191.
doi: 10.4103/1319-3767.182455
pmid: 27184635
|
[7] |
Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties[J]. Am J Gastroenterol, 2010, 105(9): 2085-2092.
doi: 10.1038/ajg.2010.143
pmid: 20372111
|
[8] |
Turner D, Ricciuto A, Lewis A, et al. STRIDE-Ⅱ: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583.
doi: 10.1053/j.gastro.2020.12.031
pmid: 33359090
|
[9] |
Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease[J]. Digestion, 2023, 104(1): 30-41.
|
[10] |
吴捷, 张添卓. 儿童炎症性肠病的研究现状及展望[J]. 临床儿科杂志, 2023, 41(11): 801-807.
|
|
Wu J, Zhang TZ. An analysis of the present status and future prospects of pediatric inflammatory bowel disease[J]. Linchuang Erke Zazhi, 2023, 41(11): 801-807.
|
[11] |
贾双珍, 孔琰, 刘前超, 等. 儿童炎症性肠病的精准治疗研究与应用[J]. 临床儿科杂志, 2025, 43(3): 226-232.
|
|
Jia SZ, Kong Y, Liu QC, et al. Application of precision therapy in pediatric inflammatory bowel disease[J]. Linchuang Erke Zazhi, 2025, 43(3): 226-232.
|
[12] |
Akutko K, Iwańczak B. Evaluation of fecal calprotectin, serum C-reactive protein, erythrocyte sedimentation rate, seromucoid and procalcitonin in the diagnostics and monitoring of Crohn's disease in children[J]. J Clin Med, 2022, 11(20): 6086.
|
[13] |
Primas C, Reinisch W, Panetta JC, et al. Model informed precision dosing tool forecasts trough infliximab and associates with disease status and tumor necrosis factor-alpha levels of inflammatory bowel diseases[J]. J Clin Med, 2022, 11(12): 3316.
|
[14] |
Sollelis E, Quinard RM, Bouguen G, et al. Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease[J]. World J Gastroenterol, 2019, 25(19): 2354-2364.
|
[15] |
Tang J, Zhang CB, Lyu KS, et al. Association of polymorphisms in C1orf106, IL1RN, and IL10 with post-induction infliximab trough level in Crohn's disease patients[J]. Gastroenterol Rep (Oxf), 2019, 8(5): 367-373.
|
[16] |
Constant BD, Khushal S, Jiang J, et al. Early inflammatory markers are associated with inadequate post-induction infliximab trough in pediatric Crohn's disease[J]. J Pediatr Gastroenterol Nutr, 2021, 72(3): 410-416.
|
[17] |
Pesole PL, Liso M, Donghia R, et al. 90K/Mac-2 BP is a new predictive biomarker of response to infliximab therapy in IBD patients[J]. Int J Mol Sci, 2023, 24(4): 3955.
|
[18] |
Buczyńska A, Grzybowska-Chlebowczyk U. Prognostic factors of biologic therapy in pediatric IBD[J]. Children (Basel), 2022, 9(10): 1558.
|
[19] |
Atia O, Pujol-Muncunill G, Navas-López VM, et al. Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix[J]. Aliment Pharmacol Ther, 2022, 56(5): 794-801.
|
[20] |
Ma C, Battat R, Parker CE, et al. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 319-330.
|
[21] |
Oussalah A, Laurent V, Bruot O, et al. Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn's disease[J]. Aliment Pharmacol Ther, 2010, 32(9): 1135-1144.
|
[22] |
Xu W, Hua Z, Wang Y, et al. The endoscopic prediction model of simple endoscopic score for Crohn's disease (SES-CD) as an effective predictor of intestinal obstruction in Crohn's disease: A multicenter long-term follow-up study[J]. Front Surg, 2022, 9: 984029.
|
[23] |
Pavelock N, Masood U, Minchenberg S, et al. Effects of obesity on the course of inflammatory bowel disease[J]. Proc (Bayl Univ Med Cent), 2019, 32(1): 14-17.
doi: 10.1080/08998280.2018.1542887
pmid: 30956572
|
[24] |
Rowan CR, McManus J, Boland K, et al. Visceral adiposity and inflammatory bowel disease[J]. Int J Colorectal Dis, 2021, 36(11): 2305-2319.
doi: 10.1007/s00384-021-03968-w
pmid: 34104989
|
[25] |
杨花花, 周旭春, 黄怡, 等. 克罗恩病英夫利昔单抗治疗失应答的影响因素分析[J]. 山东医药, 2022, 62(3): 30-34.
|
|
Yang HH, Zhou XC, Huang Y, et al. Analysis of factors affecting loss of response to infliximab in the treatment of Crohn's disease[J]. Shandong Yiyao, 2022, 62(3): 30-34.
|
[26] |
Ye XQ, Cai J, Yu Q, et al. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study[J]. Gastroenterol Rep (Oxf), 2020, 9(4): 329-338.
|